HCM Marketplace

If you’re not familiar with F-Tag 329, you need to be. This new government regulation, which took effect in December 2006, is designed to reduce unnecessary drug use and improve quality of care in nursing homes by mandating more frequent and comprehensive reviews of resident drug regimens.  It has the potential to significantly affect medication use in nursing homes. Some drugs could benefit. Others could see market share decline.

Implications for Pharma

Drug Sales in Long-Term Care: The Impact of Medicare’s New Medication Monitoring F-Tag, a research report published by ePharmaceuticals, is designed to:

1. Help companies and brand teams respond to the new F-Tag regulations
2. Illustrate the regulation’s potential impact on specific drugs and drug categories.

The report includes:

1. The results of a survey of more than 250 long-term care nurses that describes the impact of the new regulations on the ground in nursing homes.
2. A drug-by-drug analysis of the likely impact of the regulationon 223 drugs in 21 therapeutic categories

Key Questions Answered in this Report

1. What does F-Tag #329 require of nursing homes, and how could those requirements affect pharmaceuticals?
2. How are the new F-Tag requirements affecting therapeutic decisions at the point of care in nursing homes, and how might brand and managed care marketing and sales teams react?
3. How have nursing homes responded since the regulation took effect in December 2006, and what are the implications for brand and managed care marketing and sales?
4. How is use of specific drugs likely to increase or decrease in nursing homes as a result of F-Tag 329, and why?
5. How is managed care reacting, and what could that mean for drug formularies and coverage decisions?

 For more information on this report, call 877/437-4276 or email: epharm@hcpro.com.

• Reports

• Other Life Sciences Products